scholarly journals Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada

2003 ◽  
Vol 42 (8) ◽  
pp. 1438-1445 ◽  
Author(s):  
David Johnson ◽  
Yan Jin ◽  
Hude Quan ◽  
Bibiana Cujec
Keyword(s):  
Heart Failure ◽  
Angiotensin Converting Enzyme ◽  
Hospital Discharge ◽  
Enzyme Inhibitors ◽  
Beta Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers

scholarly journals Epidemiology and treatment of chronic heart failure; use of bisoprolol

2013 ◽  
Vol 154 (44) ◽  
pp. 1731-1734
Author(s):  
Viktor Nagy
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Beta Blockers ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers

The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15–20% of subjects over 80 years of age. The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists. Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure. However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure. The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies. Orv. Hetil., 154 (44), 1731–1734.

Sign in / Sign up

Export Citation Format

Share Document